AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 101 min read$HRMY

Engaging In Options Activity, Kumar Budur Exercises Options Valued At $262K In Harmony Biosciences Hldgs

Kumar Budur, Chief Medical Officer of Harmony Biosciences Hldgs (HRMY), exercised options for 22,954 shares at $30.49 each, totaling $262,978. HRMY shares are down 1.57%, trading at $41.95. The company reported 30.32% revenue growth, a 75.81% gross margin, and an EPS of 1.3. Its P/E ratio is 13.47, and its EV/EBITDA is 6.82.

Original reporting
benzinga.com
Published Sep 10, 2026, 3:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 2:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$HRMY
Neutral
medium confidence
Mentioned
$HRMY
Relevance
4/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$HRMYNeutralLow
01

Why it matters

The Form 4 filing reveals a modest insider purchase, offering limited new insight for traders.

02

Market read

New insider exercise disclosed; small size suggests low trading relevance.

03

What to watch

Potential upcoming clinical data releases could make the insider activity more meaningful if tied to pipeline milestones.

Relevance 4/10Novelty 4/10Timing: post‑filing Sep 9

Background

Harmony Biosciences (HRMY) is a commercial‑stage rare‑neurology biotech with recent positive financial metrics but modest scale.

Company-level read

Ticker impact

$HRMYNeutralMedium confidence
Context

CFO Kumar Budur exercised 22,954 HRMY options at $30.49, a $262K purchase disclosed in a Form 4 filing on Sep 9.

Expected impact

minimal upside, likely no immediate price move

Evidence & confidence

The transaction is the first public disclosure of the exercise, but the dollar amount is low for a listed biotech, limiting market reaction.

Market effects

Sector

Limited; insider activity does not materially affect the rare‑neurology biotech sector.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The insider purchase could be a routine tax‑planning move rather than a confidence signal.

Key entities

  • person
    Kumar Budur

    Chief Medical Officer of Harmony Biosciences who exercised stock options.

  • company
    Harmony Biosciences Holdings Inc.

    NASDAQ‑listed biotech (ticker HRMY).

Read at source← All news

Related articles

SEP 3
$HRMYHighAI 8/10

Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?

Harmony Biosciences (HRMY) stock rose 12.1% since last earnings. The company expects multiple clinical trial data in 2026-2027, including for pitolisant GR and epilepsy treatments. HRMY reaffirmed 2026 revenue guidance of $1B-$1.04B, with Q2 revenues up 21% sequentially. Analysts have upwardly revised estimates, and HRMY has an aggregate VGM Score of A.

finance.yahoo.com2 min
AUG 11
$HRMYMedAI 8/10

Harmony Biosciences (HRMY) Q2 2026 Earnings Call Transcript

Harmony Biosciences (HRMY) reported Q2 2026 WAKIX net revenue of $261.3 million, up 30% year over year, and confirmed 2026 revenue guidance of $1.0 billion to $1.04 billion. Net income was $75.4 million ($1.28/diluted share). Cash and investments were $962.5 million as of June 30, 2026. The company also discussed BP-205 clinical data and pipeline timelines.

fool.com10 min
AUG 5
$HRMYMedAI 8/10

Harmony Biosciences Says New Data Supports Neurology Pipeline - Harmony Biosciences Hldgs (NASDAQ:HRMY)

Harmony Biosciences (NASDAQ:HRMY) reported Q2 EPS of $1.28, above a 94-cent consensus, and sales of $261.3 million versus $248.41 million expected. WAKIX net revenue rose 30% to $261.3 million, and HRMY reiterated full-year WAKIX guidance of $1.0B to $1.04B. The company also shared Phase 1 BP-205 SAD data and plans Phase 2 studies from mid-2027.

benzinga.com5 min
AUG 4
$HRMYMed

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class…

Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. ‌ Exhibit 99.1 Harmony Biosciences Announces Record Q2 2026 Re venue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Averag

SEC EDGAR 8-K6 min
JUL 16
$HRMYLow

Harmony Biosciences PREANNOUNCES Record QuarterLY Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-10.1 2 hrmy-20260716xex10d1.htm EX-10.1 ​ ​ ​ Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (this “ Agreement ”) is entered into by and between Glenn Reicin (“ Executive ”) and Harmony Biosciences Holdings, Inc. and Harmony Biosciences Management, Inc. (together

SEC EDGAR 8-K2 min
JUN 1
$HRMYMedAI 8/10

Harmony Biosciences Holdings (HRMY): One of the Best Stocks to Buy According to AI

Harmony Biosciences (NASDAQ: HRMY) is a commercial-stage pharma focused on rare neurological diseases, with WAKIX (pitolisant) as its FDA-approved treatment for narcolepsy-related excessive daytime sleepiness and cataplexy. The company reported Q1 2026 total revenue of $215.4 million (+17% YoY) and reaffirmed 2026 net revenue guidance of over $1 billion, citing ongoing WAKIX adoption.

finance.yahoo.com4 min